Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 7 | 7 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 3 | 3 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 12 | 14 |
| 2016 | 3 | 9 | 12 |
| 2017 | 3 | 6 | 9 |
| 2018 | 1 | 5 | 6 |
| 2019 | 2 | 7 | 9 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 4 | 6 |
| 2024 | 1 | 6 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.
-
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.
-
Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024 Nov; 27(6):1201-1219.
-
Huck DM, Buckley LF, Chandraker A, Blankstein R, Weber B. Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease. J Cardiovasc Pharmacol. 2024 06 01; 83(6):511-521.
-
Yaniv B, Tanenbaum B, Kazakova V, Patel SA. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma. Leuk Res. 2024 Jul; 142:107519.
-
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.
-
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.
-
Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
-
Lechner K, Mott S, Al-Saifi R, Knipfer L, Wirtz S, Atreya R, Vieth M, Rath T, Fraass T, Winter Z, August A, Luban J, Zimmermann VS, Weigmann B, Neurath MF. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021 10; 161(4):1270-1287.e19.
-
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC?risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021 06; 13(9):783-793.